Table 1. Baseline Characteristics at the time of First VL Suppression.
| Median Values or percent at day of initial VL suppression | Overall | 1995–2000 | 2001–2005 | 2006–2011 | |
|---|---|---|---|---|---|
| n = 19,324 | n = 6,678 | n = 6,240 | n = 6,406 | ||
| VL assay detection limit < 50 copies/mL | 58% | 23% | 61% | 90% | |
| Age | 48 (42–54) | 46 (40–52) | 48 (42–54) | 51 (44–57) | |
| Female Gender | 3% | 2% | 3% | 3% | |
| Race | African American | 47% | 39% | 49% | 54% |
| White | 36% | 34% | 38% | 36% | |
| Unknown | 15% | 26% | 11% | 8% | |
| HCV co-infection | 26% | 31% | 27% | 19% | |
| Drug Abuse | 33% | 32% | 34% | 34% | |
| >30 days of non HAART ARV experience | 29% | 52% | 23% | 10% | |
| Months from HIV-Dx to viral suppression | 31 (9–74) | 33 (10–62) | 34 (9–85) | 28 (8–86) | |
| VL before ART (log) | 4.7 (4.0–5.2) | 4.6 (4.0–5.2) | 4.8 (4.1–5.3) | 4.7 (4.0–5.1) | |
| Peak VL (log) | 5.0 (4.6–5.5) | 5.0 (4.6–5.5) | 5.1 (4.7–5.6) | 5.0 (4.5–5.5) | |
| CD4 count /mm3 | 333 (191–505) | 321 (180–504) | 311 (176–475) | 367(221–531) | |
| ARV class experience | 2 classes | 61% | 72% | 51% | 59% |
| 3 classes | 22% | 20% | 25% | 22% | |
| 4 classes | 13% | 7% | 19% | 13% | |
| 5 classes | 2% | 0% | 1% | 4% | |
| 6 classes | 0% | 0% | 0% | 1% | |
| ART use last 3 months | |||||
| NRTIs | 3TC/FTC | 77% | 76% | 72% | 84% |
| TDF | 31% | 0% | 23% | 71% | |
| Other | 61% | 88% | 74% | 21% | |
| Anchor | EFV / rDRV / INSTI | 36% | 14% | 38% | 57% |
| boosted PI* | 22% | 6% | 295 | 30% | |
| unboosted PI, NVP, or other | 35% | 75% | 21% | 7% | |
| Native LDL equivalent** mg/dL | 114 (89–143) | 128 (98–160) | 115 (89–145) | 109 (87–134) | |
| Body Mass Index | 25.1 (22.4–28.3) | 24.7 (22.2–27.6) | 24.8 (22.2–28.0) | 25.5 (22.6–28.9) | |
| Statin use | 7% | 2% | 7% | 11% | |
| Non Statin lipid-lowering agent use | 4% | 4% | 6% | 4% | |
| Antihypertensive use | 26% | 20% | 27% | 32% | |
| Cardiac Aspirin use | 6% | 5% | 6% | 7% | |
Medians (followed by IQR in parentheses) or percent (followed by %). EFV: efavirenz, rDRV: ritonavir boosted darunavir, INSTI: Integrase Inhibitor, NVP: nevirapine.
*other than rDRV
**Maximum of LDL cholesterol or Non-HDL cholesterol minus 30mg/dL when off lipid-lowering therapy.